EVALUATION OF GALACTOSYLTRANSFERASE II AS A TUMOR MARKER

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$49,996.00
Award Year:
1992
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
18987
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Gentest Laboratories
3330 North Causeway Boulevard, Metairie, LA, 70002
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Sudhir K Sinha
(504) 830-4760
Business Contact:
() -
Research Institution:
n/a
Abstract
RECENT REPORTS BY SEVERAL INVESTIGATORS INDICATED SERUM LEVELS OF THE ISOENZYME OF B1-4-GALACTOSYLTRANSFERASE (GTII) CORRELATED WITH THE TUMOR BURDEN OF METASTIC CANCER PATIENTS. IN OVARIAN TUMOR PATIENTS, SUCCESSFUL CANCER THERAPY RESULTED IN DECREASED LEVELS OF SERUM GTII. PRELIMINARY STUDIES INDICATED THE VARIATION BETWEEN CANCER-ASSOCIATED AND NORMAL SERUM GT IS NOT IN THE GLYCOSYLATION BUT IN A SPECIFIC PEPTIDE FRAGMENT. THIS PROJECT WILL PURIFY CANCER-ASSOCIATED GT FROM A CELL LINE IDENTIFIED AS A GT PRODUCER. A DOUBLE LABELING TECHNIQUE AND PEPTIDE MAPPING WILL BE USED TO IDENTIFY THE PEPTIDE SEGMENTS THAT DIFFER STRUCTURALLY IN THE CANCER-ASSOCIATED AND NORMAL FORMS OF GT. STRUCTURAL IDENTIFICATION OF THE SPECIFIC PEPTIDE SEGMENT AND ANY STRUCTURAL MODIFICATION ASSOCIATED WITH IT, WILL BE USED TO PRODUCE HIGHLY SPECIFIC MONOCLONAL ANTIBODIES. ALL ASSAYS PERFORMED TO DATE ARE BASED ON ANTIBODIES PRODUCED FROM PARTIALLY PURIFIED GTII. THESE ANTIBODIES MAY CROSS REACT WITH OTHER SERUM FACTORS AND HAVE LOW SENSITIVITY. PHASE II EFFORTS WILL INCLUDE DEVELOPMENT OF A COMMERCIAL KIT TO MONITOR THE PROGRESS OF CANCER THERAPY AND PERFORMANCE OF DETAILED EVALUATION OF SENSITITIVY AND SPECIFICITY OF THE KIT, USING SERUM FROM CANCER PATIENTS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government